ABSTRACT
Whether or not Graves' hyperthyroidism can be really cured, depends on the definition of “cure.” If eradication of thyroid hormone excess suffices for the label “cure,” then all patients can be cured because total thyroidectomy or high doses of 1¹³¹I will abolish hyperthyroidism albeit at the expense of creating another disease (hypothyroidism) requiring lifelong medication with levothyroxine. I would not call this a “cure,” which I would like to define as a state with stable thyroid stimulating hormone (TSH), free thyroxine, and triiodothyronine serum concentrations in the normal range in the absence of any thyroid medication. Surgery and radioiodine are unlikely to result in so-defined cures, as their preferable aim as stated in guidelines is to cause permanent hypothyroidism. Discontinuation of antithyroid drugs is followed by 50% recurrences within 4 years; before starting therapy the risk of recurrences can be estimated with the Graves' Recurrent Events After Therapy (GREAT) score. At 20-year follow-up about 62% had developed recurrent hyperthyroidism, 8% had subclinical hypothyroidism, and 3% overt hypothyroidism related to TSH receptor blocking antibodies and thyroid peroxidase antibodies. Only 27% was in remission, and might be considered cured. If the definition of “cure” would also include the disappearance of thyroid antibodies in serum, the proportion of cured patients would become even lower.
Subject(s)
Humans , Antibodies , Antibodies, Blocking , Antithyroid Agents , Follow-Up Studies , Graves Disease , Hyperthyroidism , Hypothyroidism , Iodide Peroxidase , Receptors, Thyrotropin , Recurrence , Reference Values , Thyroid Gland , Thyroidectomy , Thyrotropin , Thyroxine , TriiodothyronineABSTRACT
PURPOSE: Hypoallergenic recombinant Der p 2 has been produced by various genetic manipulations, but mutation of a naturally polymorphic amino acid residue known to affect IgE binding has not been studied. This study aimed to determine the effect of a point mutation (S47W) of residue 47 of Der p 2 on its structure and immunoglobulin (Ig) E binding. Its ability to induce pro-inflammatory responses and to induce blocking IgG antibody was also determined. METHODS: S47 of recombinant Der p 2.0110, one of the predominant variants in Bangkok, was mutated to W (S47W). S47W secreted from Pichia pastoris was examined for secondary structure and for the formation of a hydrophobic cavity by 8-Anilino-1-naphthalenesulfonic acid (ANS) staining. Monoclonal and human IgE-antibody binding was determined by enzyme-linked immunosorbent assay. Allergen-induced degranulation by human epsilon receptor expressed-rat basophil was determined. Stimulation of the pro-inflammatory cytokine interleukin (IL)-8 release from human bronchial epithelial (BEAS2B) cells and inhibition of IgE binding to the wild type allergen by S47W-induced IgG were determined. RESULTS: S47W reduced secondary structure and failed to bind the hydrophobic ANS ligand as well as a monoclonal antibody known to be dependent on the nature of the side chain of residue 114 in an adjacent loop. It could also not stimulate IL-8 release from BEAS2B cells. IgE from house dust mite (HDM)-allergic Thais bound S47W with 100-fold weaker avidity, whereas IgE of HDM-allergic Australians did not. S47W still induced basophil degranulation, although requiring higher concentrations for some subjects. Anti-S47W antiserum-immunized mice blocked the binding of human IgE to wild type Der p 2. CONCLUSIONS: The mutant S47W had altered structure and reduced ability to stimulate pro-inflammatory responses and to bind IgE, but retained its ability to induce blocking antibodies. It thus represents a hypoallergen produced by a single mutation of a non-solvent-accessible amino acid.
Subject(s)
Animals , Humans , Mice , Antibodies, Blocking , Asian People , Basophils , Dust , Enzyme-Linked Immunosorbent Assay , Immunoglobulin E , Immunoglobulin G , Immunoglobulins , Interleukin-8 , Interleukins , Pichia , Point Mutation , PyroglyphidaeABSTRACT
Hepatocellular carcinoma (HCC) has extremely poor prognosis. Immunotherapy has emerged as a new treatment for a number of cancers. Adoptive immunotherapy is one of the important cancer immunotherapy, which relies on the various lymphocytes including cytotoxic T lymphocytes, natural killer (NK) and cytokine induced killer cells. Also, there has been advance in techniques of NK cell activation to more effectively kill the cancer cells. Of note, recently the blocking antibodies targeting programmed cell death protein 1 (PD-1) have shown promising results in diverse cancers including HCC. We report our recent experience of a patient accompanying advanced HCC with extrahepatic metastases. Disease progression had occurred after sorafenib administration, while the patient showed local tumor control and tumor marker decrease by NK cell immunotherapy combined with PD-1 inhibitor therapy. Though, there was no definite survival advantage due to impaired liver function, which might be caused by treatment related toxicities as well as cancer progression.
Subject(s)
Humans , Antibodies, Blocking , Carcinoma, Hepatocellular , Cell Death , Cytokine-Induced Killer Cells , Disease Progression , Immunotherapy , Immunotherapy, Adoptive , Killer Cells, Natural , Liver , Lymphocytes , Neoplasm Metastasis , Prognosis , Programmed Cell Death 1 Receptor , T-Lymphocytes, CytotoxicABSTRACT
PURPOSE: The specific targeting of interleukin-4 receptor α (IL4Rα) receptor offers a promising therapeutic approach for inhibition of tumor cell progression in breast cancer patients. In the current study, the in vitro efficacy of superparamagnetic iron oxide nanoparticles conjugated with anti-IL4Rα blocking antibodies (SPION-IL4Rα) via polyethylene glycol polymers was evaluated in 4T1 breast cancer cells. MATERIALS AND METHODS: Cell viability, reactive oxygen species generation, and apoptosis frequency were assessed in vitro in 4T1 cancer cell lines following exposure to SPION-IL4Rα alone or combined with doxorubicin. In addition, immunofluorescence assessments and fluorimetrywere performed to confirm the specific targeting and interaction of the developed nanocarriers with IL4Rα receptors in breast cancer cells. RESULTS: Blocking of IL4Rα receptors caused a significant decrease in cell viability and induced apoptosis in 4T1 cells. In addition, combined treatment with SPION-IL4Rα+doxorubicin caused significant increases in cell death, apoptosis, and oxidative stress compared to either SPION-IL4Rα or doxorubicin alone, indicating the enhanced therapeutic efficacy of this combination. The decrease in fluorescence intensity upon immunofluorescence and fluorimetry assays combined with increased viability and decreased apoptosis following the blocking of IL4Rα receptors confirmed the successful binding of the synthesized nanocarriers to the target sites on murine 4T1 breast cancerous cells. CONCLUSION: These results suggest that SPION-IL4Rα nanocarriers might be used for successfulreduction of tumor growth and inhibition of progression of metastasis in vivo.
Subject(s)
Humans , Antibodies, Blocking , Apoptosis , Biomarkers , Breast Neoplasms , Breast , Cell Death , Cell Line , Cell Proliferation , Cell Survival , Doxorubicin , Drug Delivery Systems , Fluorescence , Fluorescent Antibody Technique , Fluorometry , In Vitro Techniques , Interleukin-4 , Iron , Nanoparticles , Neoplasm Metastasis , Oxidative Stress , Polyethylene Glycols , Polyethylene , Polymers , Reactive Oxygen SpeciesABSTRACT
Tecnologías evaluadas: -Tecnologías actuales: electromiografía con electrodo de fibra única e ICE test;\r\n-Tecnología nueva: anticuerpos bloqueadores de acetilcolina receptores, prueba de Tensilon, prueba de estímulo repetitivo. Población: Esta prueba se puede aplicar a todas las edades y a todos los sexos, ya que la aparición de la enfermedad puede presentarse en toda la población. Perspectiva: Tercer pagador - Sistema General de Seguridad en Salud (SGSSS) colombiano. Horizonte temporal: El horizonte temporal de este AIP en el caso base corresponde a un año. Adicionalmente se reportan las estimaciones del impacto presupuestal para los años 2 y 3, bajo el supuesto de la inclusión en el POS en el año 1. Costos incluidos: Solo se tuvieron en cuenta los costos de las pruebas: -Electromiografía con electrodo de fibra única: $71.262,1; -Ice test: $26.223,3; Prueba completa de Tensilon: $24.000; -Prueba de estímulo repetitivo: $46.219,1; -Test de anticuerpos contra receptor de acetilcolina por RIA (ACRA): $45.416. Fuente de costos: Para todas las pruebas diagnósticas se utilizó el promedio ponderado estimado desde los registros de uso de servicios de 2014 SISPRO (módulo de prestación de servicios, mediante conexión OBDS), teniendo como corte de búsqueda la fecha del desarrollo de este impacto (20/10/2015). Todos los costos de las pruebas son ponderados por el número de unidades utilizadas que reporta la misma base de datos. Además, todas\r\nlas tecnologías son costeadas desde bases de aseguradores, para confirmación de precios. Resultados: Actualmente, el mercado se encuentra dominado por la electromiografía con electrodo de fibra única, la cual se encuentra dentro del plan de beneficios, pero por opinión de los realizadores, una vez que la prueba de acetilcolina receptores y de Lambert entre al plan de beneficios, se aumentará su participación, lo cual repercutirá en un ahorro al sistema, dado que dichas pruebas son menos costosas.(AU)
Subject(s)
Humans , Acetylcholine/analysis , Antibodies, Blocking/therapeutic use , Edrophonium/analysis , Electromyography/methods , Myasthenia Gravis/therapy , Reproducibility of Results , Colombia , Costs and Cost Analysis/methods , Biomedical Technology , ElectrodesABSTRACT
Programmed death-1 (PD-1) is a strong negative regulator of T lymphocytes in tumor-microenvironment. By engaging PD-1 ligand (PD-L1) on tumor cells, PD-1 on T cell surface inhibits anti-tumor reactivity of tumor-infiltrating T cells. Systemic blockade of PD-1 function using blocking antibodies has shown significant therapeutic efficacy in clinical trials. However, approximately 10 to 15% of treated patients exhibited serious autoimmune responses due to the activation of self-reactive lymphocytes. To achieve selective activation of tumor-specific T cells, we generated T cells expressing a dominant-negative deletion mutant of PD-1 (PD-1 decoy) via retroviral transduction. PD-1 decoy increased IFN-γ secretion of antigen-specific T cells in response to tumor cells expressing the cognate antigen. Adoptive transfer of PD-1 decoy-expressing T cells into tumor-bearing mice potentiated T cell-mediated tumor regression. Thus, T cell-specific blockade of PD-1 could be a useful strategy for enhancing both efficacy and safety of anti-tumor T cell therapy.
Subject(s)
Animals , Humans , Mice , Adoptive Transfer , Antibodies, Blocking , Autoimmunity , Cell- and Tissue-Based Therapy , Lymphocytes , T-Lymphocytes , T-Lymphocytes, Cytotoxic , ZidovudineABSTRACT
Adhesion events of monocytes represent an important step in inflammatory responses induced by chemokines. The β1-integrin CD29 is a major adhesion molecule regulating leukocyte migration and extravasation. Although several adhesion molecules have been known as regulators of CD29, the molecular interactions between CD29 and its regulatory adhesion molecules (such as CD98 and CD147) have not been fully elucidated. Therefore, in this study, we examined whether these molecules are functionally, biochemically, and cell-biologically associated using monocytic U937 cells treated with aggregation-stimulating and blocking antibodies, as well as enzyme inhibitors. The surface levels of CD29, CD98, and CD147 (but not CD43, CD44, and CD82) were increased. The activation of CD29, CD98, and CD147 by ligation of them with aggregation-activating antibodies triggered the induction of cell-cell adhesion, and sensitivity to various enzyme inhibitors and aggregation-blocking antibodies was similar for CD29-, CD98-, and CD147-induced U937 cell aggregation. Molecular association between these molecules and the actin cytoskeleton was confirmed by confocal microscopy and immunoprecipitation. These results strongly suggest that CD29 might be modulated by its biochemical and cellular regulators, including CD98 and CD147, via the actin cytoskeleton.
Subject(s)
Actin Cytoskeleton , Antibodies , Antibodies, Blocking , Chemokines , Enzyme Inhibitors , Immunoprecipitation , Leukocytes , Ligation , Microscopy, Confocal , Monocytes , U937 CellsABSTRACT
PURPOSE: The production of camel heavy-chain antihuman IgE (huIgE) that has the potential to block IgE-FcepsilonRI interaction and histamine release by basophils. METHODS: Camels were immunized with a synthetic loop peptide (SLP) designed in a multiple antigen peptide system (MAPS) forming SLP-MAPS immunogen. Camel polyclonal antibodies (PCAs) were produced, purified, characterized using Protein A & G, ELISA, and SDS-PAGE, and tested for their potency to block passive sensitization and histamine release of human basophils using flow cytometry (FCM) and ELISA, respectively. RESULTS: FCM data indicated that camel conventional (IgG1) and heavy chain antibodies (HCAbs; IgG2, and IgG3) had blocking activities of 43.9%, 72%, and 96.6%, respectively. Moreover, both IgG2 and IgG3 achieved remarkable inhibition rates of 93.98% and 97.05% in histamine release, respectively, whereas the IgG1inhibiting activity was 60.05%. CONCLUSIONS: Camel PCAs produced against SLP-MAPS were capable of blocking the IgE-receptor interaction and the release of histamine by basophils with superiority to HCAbs. These findings may pave the way toward the possible use of camel anti-huIgE HCAbs as blocking antibodies in the treatment of IgE-mediated allergy and asthma.
Subject(s)
Humans , Antibodies , Antibodies, Blocking , Asthma , Basophils , Camelus , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Histamine Release , Histamine , Hypersensitivity , Immunoglobulin E , Immunoglobulin G , Passive Cutaneous Anaphylaxis , Staphylococcal Protein AABSTRACT
Thrmobospondin-1 is the multifunctional protein that modulates endothelial cell and tumor cell behavior via several cell surface receptors and inhibits angiogenesis. In vitro, thrombospondin-1 alters adhesion, proliferation, motility, and survival of endothelial and cancer cells. Studies have confirmed that increased TSP-1 expression suppresses growth or metastasis of some tumors and inhibits angiogenesis. In the past three decades, inhibitors of angiogenesis have been developed as regulators target the vascular endothelial growth factor (VEGF) signaling pathway and small molecule tyrosine kinase inhibitors have been clinically approved. TSP-1 has several functional domain structures and inhibits tumor angiogenesis by engaging receptors CD36 and CD47. TSP-1 binding to CD47 dissociates it from VEGFR2, inhibiting downstream AKT activation and functional responses of endothelial cells to VEGF. Recently, macrophage phagocytosis and cytotoxic T-cell induction of tumor cells mediated by CD47-specific blocking antibodies have been proposed. These findings provide a new therapeutic paradigm for elinination of cancer cells and inhibition of angiogenesis of tumor by TSP-1.
Subject(s)
Antibodies, Blocking , Endothelial Cells , Macrophages , Neoplasm Metastasis , Phagocytosis , Protein-Tyrosine Kinases , Receptors, Cell Surface , T-Lymphocytes , Thrombospondin 1 , Vascular Endothelial Growth Factor AABSTRACT
Immune system is believed to play an important role in cancer initiation as well as its progression, as evidenced by many studies revealing suppressed, defective anti-tumor immunity in cancer patients. Modulating various components in immune surveillance, such as cytokine, antigen-presenting cells, or B/T lymphocytes, to control and eradicate cancer has been an attractive theme, however, preclinical/clinical trials have not been successful enough to introduce immunotherapy into practice. Recently, enthusiasm on cancer immunotherapy has been revived mostly due to 1) growing body of data on the mechanism of immune checkpoint in cancer, and 2) promising studies performed in advanced, solid cancer patients treated with blocking antibodies targeting cytotoxic T lymphocyte-associated antigen-4 or programmed cell death protein-1 pathways. The immune checkpoints blockade is likely to be a novel armament in cancer management as the outcomes of ongoing clinical trials are released in future.
Subject(s)
Humans , Antibodies, Blocking , Antigen-Presenting Cells , Cell Death , Immune System , Immunotherapy , LymphocytesABSTRACT
There is growing evidence that crosstalk between mantle cell lymphoma (MCL) cells and stromal microenvironments, such as bone marrow and secondary lymphoid tissues, promotes tumor progression by enhancing survival and growth as well as drug resistance of MCL cells. Recent advances in the understanding of lymphoma microenvironment have led to the identification of crucial factors involved in the crosstalk and subsequent generation of their targeted agents. In the present study, we evaluated the combinatory effect of blocking antibodies (Ab) targeting CXCR4 and VLA-4, both of which were known to play significant roles in the induction of environment-mediated drug resistance (EMDR) in MCL cell line, Jeko-1. Simultaneous treatment with anti-CXCR4 and anti-VLA-4 Ab not only reduced the migration of Jeko-1 cells into the protective stromal cells, but also enhanced sensitivity of Jeko-1 to a chemotherapeutic agent to a greater degree than with either Ab alone. These combinatorial effects were associated with decreased phosphorylation of ERK1/2, AKT and NF-kappaB. Importantly, drug resistance could not be overcome once the adhesion of Jeko-1 to the stromal occurred despite the combined use of Abs, suggesting that the efforts to mitigate migration of MCLs should be attempted as much as possible. Our results provide a basis for a future development of therapeutic strategies targeting both CXCR4 and VLA-4, such as Ab combinations or bispecific antibodies, to improve treatment outcomes of MCL with grave prognosis.
Subject(s)
Antibodies, Bispecific , Antibodies, Blocking , Bone Marrow , Cell Line , Drug Resistance , Drug Therapy , Integrin alpha4beta1 , Lymphoid Tissue , Lymphoma , Lymphoma, Mantle-Cell , NF-kappa B , Phosphorylation , Prognosis , Stromal CellsABSTRACT
<p><b>OBJECTIVE</b>To study the immunoregulation effects of Tiaomian No. 3 (TM3) for recurrent spontaneous abortion (RSA) caused by shortage of blocking antibodies.</p><p><b>METHODS</b>Totally 61 patients with RSA caused by shortage of blocking antibodies were randomly assigned to the treatment group (31 cases) and the control group (30 cases) by lot method. Patients in the treatment group were treated with TM3, while those in the control group were treated with active immunotherapy using lymphocytes of their spouses. The therapeutic course for all was 3 months. Another 10 healthy females in the same age ranges were recruited as the healthy control group. The blocking antibodies (Ab1), anti-idiotypic antibodies (Ab2), T-lymphocyte cell subsets (CD4 and CD8), serum interleukin 10 (IL-10), and macrophage colony-stimulating factor (M-CSF) levels were determined before and after treatment.</p><p><b>RESULTS</b>(1) After treatment the positive conversion rate of Ab1 and/or Ab2 was 87.1% (27/31) in the treatment group and 86.7% (26/30) in the control group, showing no statistical difference (P > 0.05). (2) In the two groups, CD4 decreased and CD8 increased. The CD4/CD8 ratio was in the normal level after treatment, showing statistical difference when compared with before treatment (P < 0.05). (3) In the two groups, IL-10 and M-CSF levels were higher after treatment, showing statistical difference when compared with before treatment (P < 0.05). (4) The 1-year conception rate was 58.1% (18/31) in the treatment group, significantly higher than that in the control group (46.7%, 14/30, P < 0.05).</p><p><b>CONCLUSIONS</b>TM3 could promote the positive conversion rate of Ab1, promote the production of IL-10 and M-CSF cytokines, thus strengthening the protection for fetus by the mother and the normal maintenance for pregnancy. The 1-year successful pregnancy rate obviously increased in the treatment group.</p>
Subject(s)
Adult , Female , Humans , Pregnancy , Abortion, Habitual , Drug Therapy , Allergy and Immunology , Antibodies, Anti-Idiotypic , Antibodies, Blocking , CD4-CD8 Ratio , Drugs, Chinese Herbal , Pharmacology , Therapeutic Uses , Immunotherapy, Active , Interleukin-10 , Blood , Macrophage Colony-Stimulating Factor , Blood , Phytotherapy , T-Lymphocyte SubsetsABSTRACT
Considering that α-1 repeat region may be involved in the ion binding and translocation of Na(+)-Ca(2+) exchanger (NCX), it is possible that the antibodies against NCX α-1 repeat may have a crucial action on NCX activity. The aim of the present study is to investigate the effect of antibody against α-1 repeat (117-137), designated as α-1(117-137), on NCX activity. The antibody against the synthesized α-1(117-137) was prepared and affinity-purified. Whole-cell patch clamp technique was used to study the change of Na(+)-Ca(2+) exchange current (I(Na/Ca)) in adult rat cardiomyocytes. To evaluate the functional specificity of this antibody, its effects on L-type Ca(2+) current (I(Ca,L)), voltage-gated Na(+) current (I(Na)) and delayed rectifier K(+) current (I(K)) were also observed. The amino acid sequences of α-1(117-137) in NCX and residues 1 076-1 096 within L-type Ca(2+) channel were compared using EMBOSS Pairwise Alignment Algorithms. The results showed that outward and inward I(Na/Ca) were decreased by the antibody against α-1(117-137) dose-dependently in the concentration range from 10 to 160 nmol/L, with IC(50) values of 18.9 nmol/L and 22.4 nmol/L, respectively. Meanwhile, the antibody also decreased I(Ca,L) in a concentration-dependent manner with IC(50) of 22.7 nmol/L. No obvious effects of the antibody on I(Na) and I(K) were observed. Moreover, comparison of the amino acid sequences showed there was 23.8% sequence similarity between NCX α-1(117-137) and residues 1 076-1 096 within L-type Ca(2+) channel. These results suggest that antibody against α-1(117-137) is a blocking antibody to NCX and can also decrease I(Ca,L) in a concentration-dependent manner, while it does not have obvious effects on I(Na) and I(K).
Subject(s)
Animals , Rats , Amino Acid Sequence , Antibodies, Blocking , Metabolism , Pharmacology , Calcium Channel Blockers , Pharmacology , Calcium Channels, L-Type , Genetics , Allergy and Immunology , Metabolism , Guinea Pigs , Membrane Potentials , Molecular Sequence Data , Myocytes, Cardiac , Metabolism , Physiology , Patch-Clamp Techniques , Rats, Wistar , Sodium-Calcium Exchanger , Genetics , Allergy and ImmunologyABSTRACT
Introducción. El procedimiento estándar para el diagnóstico de la rabia requiere de muestras frescas del cerebro infectado, que se estudian mediante las técnicas de inmunofluorescencia directa y la inoculación en ratones. No obstante, a veces se necesita estudiar cerebros infectados con rabia mediante inmunohistoquímica de material fijado en aldehídos, pero los anticuerpos comerciales que se requieren son escasos y costosos. Objetivos. Elaborar un antisuero antirrábico y probar su efectividad para reconocer antígenos de rabia en tejido cerebral preservado en aldehídos. Materiales y métodos. Se inocularon conejos con una vacuna antirrábica producida en células Vero. Se obtuvo un antisuero que fue probado mediante inmunohistoquímica en cortes de cerebro de ratones infectados con rabia, obtenidos en diferentes condiciones experimentales y fijados en aldehídos. Además, se ensayó su utilidad en material de colección histopatológica de casos de rabia humana. Resultados. Se demostró la especificidad del antisuero obtenido para la detección inmunohistoquímica de antígenos de la rabia en tejido nervioso fijado con aldehídos y procedente de material experimental y del archivo histopatológico. Además, el antisuero resultó ser útil para la detección del virus rábico en condiciones que se consideran desfavorables para la preservación de antígenos. Conclusiones. La inoculación de vacuna antirrábica en conejos es un procedimiento fácil y seguro para la obtención de antisuero útil para la detección de antígenos de la rabia en muestras de tejido nervioso. Los cortes obtenidos con vibrátomo preservan mejor la antigenicidad en comparación con los tejidos incluidos en parafina, y permiten acortar el tiempo para hacer el diagnóstico inmunohistoquímico de la rabia.
Introduction. The standard procedure for rabies diagnosis requires fresh samples of infected brain to be analyzed by two techniques, direct immunofluorescence and inoculation in mice. Rabies-infected, aldehyde-fixed brain tissues can be examined by immunohistochemistry, but the required commercial antibodies are scarce and expensive. Objectives. An anti-rabies antiserum was produced and tested to evaluate the effectiveness of rabies antigen detection in aldehyde preserved brain tissue. Materials and methods. Rabbits were inoculated with a rabies vaccine produced in Vero cells (origin-African green monkey kidney). Anti-rabies antiserum was obtained and tested by immunohistochemistry in aldehyde-fixed brain sections of rabies-infected mice. Several experimental conditions were assayed. The usefulness of the antiserum in human pathology samples was also tested. Results. The specificity of the antiserum was demonstrated for immunohistochemical detection of rabies antigen in fixed aldehydes nervous tissue both from experimental material and pathology archival collection. In addition, the antiserum was successful in detecting rabies virus under conditions that have been considered unfavorable for the preservation of antigens. Conclusions. The inoculation of rabies vaccine in rabbits is an easy and safe procedure for obtaining antiserum useful for the detection of rabies antigen in samples of nervous tissue. Sections obtained on vibratome better preserve the viral antigenicity in comparison with paraffin-embedded tissues. This methods permit less expensive and more rapid immunohistochemical diagnosis of rabies.
Subject(s)
Antibodies, Blocking , External Fixators , Rabies , Rabies Vaccines , Rabies virus , Tissue Fixation , ImmunohistochemistryABSTRACT
Blockade of signal 1 or 2 for T-cell activation by the use of anti-CD45RB and anti-CD154 monoclonal antibodies (mAb) (two-signal blockade) has been proven effective in preventing or delaying graft rejection. However, the mechanisms of its immunomodulatory effects are clearly unknown and the present studies were performed to determine how the two-signal blockade modulate allogeneic immune responses, especially T-cell mediated cellular immunity, in a murine skin allograft model. We now report on the profound inhibition of alloreactive T cells by two-signal blockade via CD4-dependent mechanisms. C57BL/6 mice of BALB/c skin allograft were treated with anti-CD45RB, anti-CD154, CTLA4-Ig, or their combinations. For depletion of CD4 or CD8 T cells, the recipients received CD4-depleting or CD8-depleting mAb. We confirmed that survival of skin allograft was markedly prolongated in the two-signal blockade-treated group. In depletion study, anti-CD45RB, anti-CD154 and CD4-depleting mAb-treated group showed acute rejection of skin allograft in contrast to CD8-depleting group treated with the two-signal blockade. In the group treated with the two-signal blockade, the proportions of CD4+CD45RB(low)and CD8+CTLA-4 regulatory T cells were increased while effector CD8+ T cells, including IFN-gamma-secreting and CD8+CD62L(low)T cells, were decreased when compared with non-treated group. In contrast, the CD4-depleted group treated with the two-signal blockade resulted in recovery from immunoregulatory effects of two-signal blockade. In addition, results of IL-4 and IL-10 production were also showed CD4-dependence. Therefore, the two-signal blockade is accompanied by CD4-dependent mechanisms in allogeneic skin transplantation.
Subject(s)
Mice , Male , Animals , Transplantation, Homologous , T-Lymphocytes, Regulatory/cytology , Skin Transplantation/immunology , Signal Transduction/drug effects , Mice, Inbred C57BL , Mice, Inbred BALB C , Lymphocyte Depletion , Lymphocyte Activation/immunology , Interleukin-4/biosynthesis , Interleukin-10/biosynthesis , Graft Rejection/immunology , Flow Cytometry , Cytotoxicity, Immunologic/immunology , CD8-Positive T-Lymphocytes/cytology , CD40 Ligand/immunology , CD4-Positive T-Lymphocytes/cytology , Leukocyte Common Antigens/immunology , CD4 Antigens/immunology , Antibodies, Monoclonal/administration & dosage , Antibodies, Blocking/administration & dosageABSTRACT
BACKGROUND: Nerve growth factor (NGF) promotes the survival and differentiation of vertebrate neurons, and their actions are mediated by two classes of cell surface receptors: tyrosine kinase A receptor (TrkA) and p75 neurotrophic receptor (p75NTR). We evaluated the role of NGF receptors in neuronal survival and the physical interactions between them. METHODS: Organotypic hippocampal slices were obtained from 5 to 7-day-old rat pups and were grown for 14 days in vitro. The expression of the TrkA and p75NTR was evaluated by the western blot and immunohistochemical methods. The neuroprotective effect of NGF on the blocking of antibody-induced neuronal cell death was tested by the application of NGF (0, 50 and 150 ng/ml) to the culture media in the presence of 200 ng/ml of blocking antibodies against TrkA and p75NTR. Functional interactions between the two receptors were examined using the immunoprecipitation method. RESULTS: TrkA and p75NTR were co-expressed in the principal neurons of the hippocampal slice culture, and the expression level was increased time dependently until 14 days of culture. The blocking antibody against each receptor induced neuronal damage in time and dose-dependent manners. NFG delayed or prevented the blocking antibody from inducing neuronal damage. Results from the immunoprecipitation experiment showed physical interactions between the two NGF receptors. CONCLUSIONS: Our results indicate that the co-expressed NGF receptors, TrkA and p75NTR, might have protective roles in the survival of neuronal cells through the cooperative interactions between them.
Subject(s)
Animals , Rats , Antibodies, Blocking , Blotting, Western , Cell Death , Culture Media , Immunoprecipitation , Nerve Growth Factor , Neurons , Neuroprotective Agents , Protein-Tyrosine Kinases , Receptor, Nerve Growth Factor , Receptors, Cell Surface , Receptors, Nerve Growth Factor , VertebratesABSTRACT
A 33 years old multigravida lady presented at 8 weeks of gestation for booking, with a history of previous three caesarean sections. In 1995, her first pregnancy ended up in spontaneous abortion. The development of classical symptoms of MG during her second pregnancy and delayed recovery from nondepolarizing muscle relaxant [used for general anaesthesia] led to the suspicion of MG. The neonate also suffered from transient neonatal MG. Later on, she was investigated and found to have raised anticholinesterase receptor antibodies [117 nmol/L], cholinesterase level [4355 micro /L] and serum anti-DNA [3.9 I.V/ml]. Other antibodies including ANA, AMSA and AMA were negative. The treatment for MG started with an anti-cholinesterase agent in a dose of 60 mg daily. Thymectomy was carried out in 1998 for enlarged thymus gland and her symptoms further improved. Thereafter, the dose of anti-cholinesterase drug was reduced to half i.e., 30 mg daily during subsequent three pregnancies. The present pregnancy was supervised intensively by an obstetrician and neurologist. An elective C. section with bilateral tubal ligation was carried out on term under spinal anaesthesia. A male baby weighing 4 kg was delivered with an APGAR scores of eight at one minute and ten at five minutes. The patient continued her normal oral therapy before and after the operation. Her puerperium was uneventful
Subject(s)
Humans , Female , Myasthenia Gravis/therapy , Pregnancy, High-Risk , Neuromuscular Junction Diseases , Cesarean Section/statistics & numerical data , Antibodies, Blocking , Receptors, Nicotinic , Acetylcholine , Placenta , Myasthenia Gravis, Neonatal , Delivery, Obstetric , Postpartum Period , Maternal Mortality , Obstetric Labor, PrematureABSTRACT
Betaig-h3 (betaig-h3) is a secretory protein composed of fasciclin I-like repeats containing sequences that allows binding of integrins and glycosaminoglycans in vivo. Expression of betaig-h3 is responsive to TGF-beta and the protein is found to be associated with extracellular matrix (ECM) molecules, implicating betaig-h3 as an ECM adhesive protein of developmental processes. We previously observed predominant expression of betaig-h3 expression in the basement membrane of proximal tubules of kidney. In this study, the physiological relevance of such localized expression of betaig-h3 was examined in the renal proximal tubular epithelial cells (RPTEC). RPTEC constitutively expressed betaig-h3 and the expression was dramatically induced by exogenous TGF-beta1 treatment. betaig-h3 and its second and fourth FAS1 domain were able to mediate RPTEC adhesion, spreading and migration. Two known alpha3beta1 integrin-interaction motifs including aspartatic acid and isoleucine residues, NKDIL and EPDIM in betaig-h3 were responsible to mediate RPTEC adhesion, spreading, and migration. By using specific antibodies against integrins, we confirmed that alpha3beta1 integrin mediates the adhesion and migration of RPTECs on betaig-h3. In addition, it also enhanced proliferation of RPTECs through NKDIL and EPDIM. These results indicate that betaig-h3 mediates adhesion, spreading, migration and proliferation of RPTECs through the interaction with alpha3beta1 integrin and is intimately involved in the maintenance and the regeneration of renal proximal tubular epithelium.
Subject(s)
Humans , Amino Acid Motifs , Antibodies, Blocking/immunology , Cell Adhesion/physiology , Cell Movement/physiology , Cell Proliferation , Cells, Cultured , Epithelial Cells/drug effects , Extracellular Matrix Proteins/chemistry , Integrin alpha3beta1/chemistry , Kidney Tubules, Proximal/cytology , Peptides/chemistry , Protein Interaction Mapping , Transforming Growth Factor beta/chemistryABSTRACT
<p><b>OBJECTIVE</b>To explore the effect of Chinese herbal medicine Baotai Granule (BTG, a self-made preparation) on CD antigen blocking efficiency, prolactin (PRL) and progesterone (P) in patients with recurrent spontaneous abortion (RSA).</p><p><b>METHODS</b>Thirty-four women suffered from RSA were treated with BTG, twice every day, 1 package (10 g) in each time by orally intake. Changes of the efficiency of serum blocking antibody in them to the CD antigen in their husband's peripheral T-lymphocytes before and after treatment were observed. And the changes of blood levels of PRL and P were also monitored.</p><p><b>RESULTS</b>Fetus had successfully protected in 30 women (88.2%), in them, the efficiency of blocking to CD3, CD4 and CD8 after treatment were all higher than that before treatment, and levels of PRL and P in peripheral blood increased along with the increase of gestational age, while no obvious change was found in those who failed to complete pregnancy.</p><p><b>CONCLUSION</b>Chinese herbal medicine could protect the fetus by regulating the response between endocrine and immunity network during pregnancy.</p>
Subject(s)
Adult , Female , Humans , Pregnancy , Abortion, Habitual , Drug Therapy , Allergy and Immunology , Antibodies, Blocking , Antigens, CD , Allergy and Immunology , Drugs, Chinese Herbal , Therapeutic Uses , Phytotherapy , Progesterone , Blood , Prolactin , Blood , T-Lymphocytes , Allergy and ImmunologyABSTRACT
During chronic inflammatory response, mono- cytes/macrophages produce 92-kDa matrix metalloproteinase-9 (MMP-9), which may contribute to their extravasation, migration and tissue remodeling. Activation of peroxisome proliferator- activated factor receptor-gamma (PPAR-gamma) has been shown to inhibit MMP-9 activity. To evaluate whether ox-LDL, a PPAR-gamma activator, inhibits PMA-induced MMP-9 expression and activity, and if so, whether CD36 and PPAR-gamma are involved in this process, we investigated the effect of ox-LDL on MMP-9 expression and activity in PMA-activated human monocytic cell line U937. PMA-induced MMP-9 expression and activity were suppressed by the treatment with ox-LDL (50 micrigram/ml) or PPAR-gamma activators such as troglitazone (5 micrometer), ciglitazone (5 micrometer), and 15d- PGJ2 (1 micrometer) for 24 h. This ox-LDL or PPAR-gamma activator-mediated inhibition of micrometer P-9 activity was diminished by the pre-treatment of cells with a blocking antibody to CD36, or PGF2a (0.3 micrometer), which is a PPAR-gamma inhibitor, as well as overexpression of a dominant-negative form of CD36. Taken together, these results suggest that ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-gamma.